Join Abzena’s head of Chemistry from our Bristol, PA Bioconjugation Development and Manufacturing site for the Outsourced Pharma Capacity Update focused on ADCs.

Presentation: Accelerating ADC Development and Manufacturing with ThioBridge™ Conjugation and Linker Technology.

Speaker: Francisco Velázquez , Senior Director of Chemistry, Abzena

This presentation will highlight ThioBridge^TM as an efficient site-specific conjugation technology to generate ADCs and other conjugate modalities such as oligoconjugates (AOCs) and conjugates for diagnostic applications.

Attendees will gain insight into:

• ThioBridge^TM conjugation technology insights.  How the technology works, and its advantages over stochastic conjugation technologies.
• Modulation of Drug-Antibody Ratio (DAR) using ThioBridge as an effective feature to optimize therapeutic activity.
• In vitro and in vivo stability of ADCs generated using ThioBridge^TM
• Optimization of linker architecture to enhance in vivo efficacy of ThioBridge^TM ADCs.  In vivo data for relevant ADCs generated using ThioBridge^TM technology
• ThioBridge^TM linker-payload and ADC manufacturing considerations.

Click here to register